Bone Biologics Co. (NASDAQ:BBLGW – Get Free Report)’s stock price traded down 20.1% during trading on Wednesday . The stock traded as low as $13.50 and last traded at $13.50. 200 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 2,005 shares. The stock had previously closed at $16.90.
Bone Biologics Stock Down 20.1%
The stock has a fifty day moving average of $18.28 and a 200 day moving average of $33.47.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Read More
- Five stocks we like better than Bone Biologics
- Asset Allocation Strategies in Volatile Markets
- $30B AI Opportunity: Will It Power Meta’s Next Surge?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Microsoft Could Rally as EU Antitrust Case Nears Resolution
- What is a penny stock? A comprehensive guide
- Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
